普拉克索联合多巴丝肼治疗帕金森病的疗效  

Efficacy of pramipexole combined with levodopa and benserazide hydrochloride in the treatment of Parkinson′s disease

作　　者：杜洋 何晓非[1] DU Yang;HE Xiaofei(Department of Neurology,Suining Central Hospital,Sichuan Province,Suining 629000,China)

机构地区：[1]四川省遂宁市中心医院神经内科,629000

出　　处：《临床合理用药杂志》2023年第30期22-25,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察普拉克索联合多巴丝肼治疗帕金森病的疗效。方法选取2019年1月—2022年12月遂宁市中心医院收治的帕金森病患者90例,按照双色球法分为对照组与观察组,每组45例。对照组予以多巴丝肼片,观察组予以多巴丝肼片联合盐酸普拉克索片,2组均连续治疗12周。比较2组临床疗效,症状缓解时间,治疗前与治疗12周后焦虑自评量表评分、抑郁自评量表评分、血清超敏C反应蛋白(hs-CRP)水平,不良反应。结果观察组总有效率高于对照组(95.56%vs.77.78%,χ^(2)=6.154,P=0.013)。观察组入睡困难、早醒、噩梦、幻觉缓解时间短于对照组(P<0.01)。治疗12周后,2组焦虑自评量表评分、抑郁自评量表评分较治疗前降低,且观察组低于对照组(P<0.01);2组血清hs-CRP水平较治疗前降低,且观察组低于对照组(P<0.01)。观察组与对照组不良反应总发生率比较,差异无统计学意义(6.67%vs.13.33%,χ^(2)=0.494,P=0.482)。结论帕金森病患者在多巴丝肼治疗基础上联合普拉克索治疗,能进一步提高疗效,缩短症状缓解时间,还可更好地改善负面情绪,减轻炎性反应,且不会明显增加不良反应。Objective To observe the efficacy of pramipexole combined with levodopa and benserazide hydrochloride in the treatment of Parkinson′s disease.Methods Ninety cases of Parkinson′s disease patients admitted to Suining Central Hospital from January 2019 to December 2022 were selected and divided into the control group and the observation group according to the bicolor method,with 45 cases in each group.The control group was treated with levodopa and benserazide hydrochloride tablets,and the observation group was treated with levodopa and benserazide hydrochloride tablets combined with pramipexole dihydrochloride tablets,and both groups were treated continuously for 12 weeks.The clinical efficacy,symptoms relief time,Anxiety Self-assessment Scale score,Depression Self-assessment Scale score,serum hs-CRP level before and after 12 weeks of treatment,and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(95.56%vs.77.78%,χ^(2)=6.154,P=0.013).The relief time of difficulty in falling asleep,early awakening,nightmares and hallucinations in the observation group were shorter than those in the control group(P<0.01).After 12 weeks of treatment,the Anxiety Self-assessment Scale score and Depression Self-assessment Scale score of the two groups were lower than those before treatment,and the observation group were lower than those of the control group(P<0.01);Serum hs-CRP level of the two groups was lower than that before treatment,and the observation group was lower than that of the control group(P<0.01).The difference in the total incidence of adverse reactions between the observation group and the control group was not statistically significant(6.67%vs.13.33%,χ^(2)=0.494,P=0.482).Conclusion On the basis of levodopa and benserazide hydrochloride,combined with pramipexole treatment can further improve the efficacy of Parkinson′s disease patients,shorten the relief time of symptoms,and also better improve the negative em

关 键 词：帕金森病 普拉克索 多巴丝肼 负面情绪 治疗结果 安全性 

分 类 号：R742.5[医药卫生—神经病学与精神病学]